Physician profile
Deborah Galloway
NPI 1346292869
$11,115.22
in general payments reported to CMS, 2019-2025
56 companies · $3,443 in 2025
The $3,443 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2021: $267 · 2022: $1,353 · 2023: $2,457 · 2024: $3,246 · 2025: $3,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,126 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,126.43 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,233.82 | 2022-2025 | |
| Lundbeck LLC | $940.13 | 2022-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $810.74 | 2022-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $696.47 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $477.90 | 2022-2025 | Rytary, Crexont |
| Harmony Biosciences LLC | $311.62 | 2023-2025 | Wakix |
| Medtronic, INC. | $299.55 | 2024 | Percept PC Brainsense |
| Takeda Pharmaceuticals U.S.A., INC. | $251.38 | 2023-2025 | Hyqvia |
| Kyowa Kirin, INC. | $230.59 | 2023-2024 | Nourianz |
| Sunovion Pharmaceuticals INC. | $223.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $221.73 | 2019-2025 | Soliris, Ultomiris |
| Lilly USA, LLC | $216.02 | 2023-2025 | Kisunla, Reyvow, Emgality |
| Ucb, INC. | $205.92 | 2021-2024 | Briviact, Rystiggo |
| Grifols USA, LLC | $174.53 | 2023-2025 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $166.54 | 2024-2025 | Rexulti |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.87 | 2022-2024 | Uplizna |
| Scilex Pharmaceuticals INC. | $154.01 | 2023-2024 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $153.72 | 2021-2023 | Ajovy |
| Axsome Therapeutics, INC. | $151.88 | 2024-2025 | Symbravo, Sunosi |
| Acadia Pharmaceuticals INC | $150.34 | 2023-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $145.61 | 2024-2025 | Wainua |
| Merz Pharmaceuticals, LLC | $139.66 | 2025 | Xeomin, Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $124.50 | 2022 | |
| Tanabe Pharma America, INC. | $120.55 | 2024-2025 | Radicava |
| Mannkind Corporation | $119.20 | 2021 | |
| Intuity Medical INC | $115.04 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Argenx US, INC. | $91.21 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Acorda Therapeutics, INC | $85.55 | 2023-2024 | Inbrija |
| Octapharma USA, INC. | $84.29 | 2024 | Panzyga |
| Jazz Pharmaceuticals INC. | $69.42 | 2023-2024 | |
| Tg Therapeutics, INC. | $61.75 | 2024-2025 | |
| Almatica Pharma LLC | $60.04 | 2022-2023 | Gralise |
| Catalyst Pharmaceuticals, INC. | $59.60 | 2022-2023 | Fycompa |
| Genzyme Corporation | $55.08 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $52.58 | 2025 | Dysport |
| Impel Pharmaceuticals INC. | $47.84 | 2022-2023 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $39.39 | 2025 | Horizant |
| Neurelis, INC. | $29.36 | 2023 | Valtoco |
| Inspire Medical Systems, INC. | $28.09 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $27.80 | 2024 | Amvuttra |
| Upsher-Smith Laboratories LLC | $27.09 | 2022 | |
| Springworks Therapeutics, INC. | $26.13 | 2025 | Gomekli |
| Revance Therapeutics, INC. | $25.97 | 2024 | Daxxify |
| Ani Pharmaceuticals, INC. | $25.71 | 2023 | Purified Cortrophin Gel |
| Microtransponder, INC. | $25.44 | 2024 | |
| Abbott Laboratories | $23.61 | 2022 | |
| Biogen, INC. | $22.41 | 2023 | Plegridy, Vumerity |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Averitas Pharma INC. | $19.85 | 2025 | Qutenza |
| Sk Life Science, INC. | $18.15 | 2022 | |
| Horizon Therapeutics Plc | $17.97 | 2023 | Uplizna |
| Grt US Holding, INC. | $17.95 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.97 | 2025 | Ponvory |
| Protega Pharmaceutials INC | $14.96 | 2024 | Roxybond |
| Otter Pharmaceuticals, LLC | $14.33 | 2025 | Sympazan |
| Tonix Medicines, INC. | $13.83 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.